CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-02-16 | Arkowitz David Chief Financial Officer | Sale 10b5-1 | −3,939 | $1.08 | $4K | 182,442 |
| 2024-02-15 | Arkowitz David Chief Financial Officer | Exercise or conversion 10b5-1 | +10,625 | 186,381 | ||
| 2024-02-15 | Arkowitz David Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −10,625 | 31,875 | ||
| 2024-02-14 | Arkowitz David Chief Financial Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +213,750 | 213,750 | ||
| 2024-02-14 | Arkowitz David Chief Financial Officer | Grant or award · Stock Option (Right to Buy) 10b5-1 | +287,905 | 287,905 | ||
| 2024-02-14 | Arkowitz David Chief Financial Officer | Grant or award · Restricted Stock Units 10b5-1 | +35,625 | 35,625 | ||
| 2023-10-30 | Arkowitz David Chief Financial Officer | Sale 10b5-1 | −4,066 | $1.35 | $5K | 175,756 |
| 2023-10-27 | Arkowitz David Chief Financial Officer | Exercise or conversion 10b5-1 | +13,209 | 179,822 | ||
| 2023-10-27 | Arkowitz David Chief Financial Officer | Exercise or conversion · Restricted Stock Units 10b5-1 | −13,209 | 13,209 | ||
| 2023-04-27 | Arkowitz David Chief Financial Officer | Grant or award · Restricted Stock Units 10b5-1 | +26,418 | 26,418 | ||
| 2023-04-27 | Arkowitz David Chief Financial Officer | Grant or award | +42,500 | 166,613 | ||
| 2023-02-03 | Arkowitz David Chief Financial Officer | Grant or award · Restricted Stock Units | +42,500 | 42,500 | ||
| 2023-02-03 | Arkowitz David Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +85,000 | 85,000 | ||
| 2022-10-27 | Arkowitz David Chief Financial Officer | Grant or award | +42,500 | 112,992 | ||
| 2022-07-05 | Arkowitz David Chief Financial Officer | Grant or award | +63,492 | $3.15 | $200K | 65,492 |
| 2022-06-15 | Arkowitz David Chief Financial Officer | Exercise or conversion | +5,000 | 70,492 | ||
| 2022-06-15 | Arkowitz David Chief Financial Officer | Exercise or conversion · Restricted Stock Units | −5,000 | 0 | ||
| 2022-02-04 | Arkowitz David | Grant or award · Stock Option (Right to Buy) | +190,000 | 190,000 | ||
| 2021-06-01 | Arkowitz David Chief Financial Officer | Grant or award · Stock Options (right to buy) | +270,000 | 270,000 | ||
| 2021-06-01 | Arkowitz David Chief Financial Officer | Grant or award · Restricted Stock Units | +5,000 | 5,000 |
Page 1 of 1 · 20 trades